Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Silence Therapeutics (SLN – Research Report) and Monopar Therapeutics Inc (MNPR – Research Report).
Silence Therapeutics (SLN)
In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Silence Therapeutics, with a price target of $80.00. The company’s shares closed last Tuesday at $6.70, close to its 52-week low of $4.55.
According to TipRanks.com, Trucchio is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Silence Therapeutics with a $44.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Monopar Therapeutics Inc (MNPR)
JonesTrading analyst Soumit Roy maintained a Hold rating on Monopar Therapeutics Inc today. The company’s shares closed last Tuesday at $0.43, close to its 52-week low of $0.40.
According to TipRanks.com, Roy has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Monopar Therapeutics Inc.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
